Voyager Therapeutics (VYGR) Tops Q4 EPS by 154c

Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of $1.25, $1.54 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $90.06 million versus the consensus estimate of $20.63 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• Raymond James on Malibu Boats (MBUU): 'continued soft retail environment'
• Piper Sandler: 'Amazon.com (AMZN) AMZN Looks Best Positioned'